Matches in Nanopublications for { ?s ?p "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP365974.RABCbwBenpZfOBdgXaZ4j8RqMjqMhc3tenzqQPgibq1Yk130_assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP365974.RABCbwBenpZfOBdgXaZ4j8RqMjqMhc3tenzqQPgibq1Yk130_provenance.
- assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.
- NP525815.RAj-esy8TLna6jaGVeh0a4DC9zKWDhIeNKuUwsFmgAWXM130_assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525815.RAj-esy8TLna6jaGVeh0a4DC9zKWDhIeNKuUwsFmgAWXM130_provenance.
- NP1105069.RA9O68zkAxdenEFl1t2PluXx5HCLIB9VSIHcizRqcz-7A130_assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105069.RA9O68zkAxdenEFl1t2PluXx5HCLIB9VSIHcizRqcz-7A130_provenance.